GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BGI Genomics Co Ltd (SZSE:300676) » Definitions » Cash, Cash Equivalents, Marketable Securities

BGI Genomics Co (SZSE:300676) Cash, Cash Equivalents, Marketable Securities : ¥4,313 Mil (As of Mar. 2025)


View and export this data going back to 2017. Start your Free Trial

What is BGI Genomics Co Cash, Cash Equivalents, Marketable Securities?

BGI Genomics Co's quarterly cash, cash equivalents, marketable securities declined from Sep. 2024 (¥4,712.56 Mil) to Dec. 2024 (¥4,309.68 Mil) but then increased from Dec. 2024 (¥4,309.68 Mil) to Mar. 2025 (¥4,313.46 Mil).

BGI Genomics Co's annual cash, cash equivalents, marketable securities declined from Dec. 2022 (¥6,391.67 Mil) to Dec. 2023 (¥5,485.95 Mil) and declined from Dec. 2023 (¥5,485.95 Mil) to Dec. 2024 (¥4,309.68 Mil).


BGI Genomics Co Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for BGI Genomics Co's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BGI Genomics Co Cash, Cash Equivalents, Marketable Securities Chart

BGI Genomics Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,430.07 8,639.36 6,391.67 5,485.95 4,309.68

BGI Genomics Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,260.82 4,943.36 4,712.56 4,309.68 4,313.46

BGI Genomics Co Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


BGI Genomics Co  (SZSE:300676) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


BGI Genomics Co Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of BGI Genomics Co's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


BGI Genomics Co Business Description

Industry
Traded in Other Exchanges
N/A
Address
21 Hongan Third Street, Dong, Huada Complex Park, Yantian District, Shenzhen, CHN, 518083
BGI Genomics Co Ltd is a China-based company principally engaged in the provision of genomic class diagnosis and research services through the application of biotechnology. It offers its services in various research areas, such as agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug discovery. The company mainly provides services for domestic and overseas academic institutions hospitals, medical institutions and others.
Executives
Xu Qian Secretary Dong
Zhao Li Jian Directors, executives
Wang Yu Jue Directors, executives
Wang Jian Director
Liu Na Executives
Sun Ying Jun Director
Yin Ye Directors, executives
Du Yu Tao Directors, executives
Li Song Gang Supervisors
Hu Yu Jie Supervisors
Li Zhi Ping Executives
Chen Yi Qing Executives
Li Wen Qi Supervisors

BGI Genomics Co Headlines

No Headlines